A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a substantial societal return… read more.
A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan study. And more… read more.
Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading… read more.
Pharmacist Deborah Evans runs a weight-management clinic at Remedi Health in Winchester. She has helped many people to lose weight and improve their health using the GLP-1 receptor… read more.
Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy… read more.
Eli Lilly and Company announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program… read more.
Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher… read more.
Fizzy water might aid weight loss by boosting blood glucose uptake and metabolism—the rate at which the body uses and converts energy—but the effects are so small, drinking… read more.
A new Cochrane review has found that calorie labelling of food on menus and products leads people to choose slightly fewer calories. The research team, led by scientists… read more.
Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma Corporation announced that Eli Lilly Japan received manufacturing and marketing authorization in Japan from the Japanese Ministry of Health, Labour… read more.
A meta- analysis of studies evaluating the efficacy and safety of various glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for treating obesity in adults without diabetes, suggests… read more.
NICE (UK): 1.1 Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
